Bristol Myers Squibb
-
BMS GPRC5D CAR-T Arlo-cel Shows Deep Responses After BCMA Failure
Phase 1 data show 87% response and 18-month PFS; pivotal phase 2 met goals but BMS withheld numbers as phase 3 begins.
Most read
-
Minnesota Makes Personal Finance Course Mandatory for High School Graduation
-
UK Households With £10,000 Risk Losing £300 To Low Interest Rates
-
Selangor International Care Expo in Kuala Lumpur 2026
-
Asian & Oceanian Epilepsy Congress 2026 in Kuala Lumpur
-
Baby & Beyond Maternity Expo in Kuala Lumpur 2026
-
Amgen and AstraZeneca Combination Therapy Shows Unprecedented Survival Gains in Lung Cancer
-
Moderna’s mRNA Platform Enables Rapid Personalized Cancer Vaccines
-
Evaluating Skyrizi’s Efficacy and Market Position in Crohn’s Disease Care
-
How Personalized mRNA Vaccines Target Neoantigens to Beat Melanoma
-
Understanding How Novel Drug Targets Aim to Slow Alzheimer’s
-
BMS GPRC5D CAR-T Arlo-cel Shows Deep Responses After BCMA Failure
-
Understanding the FDA’s Accelerated Approval of Iberdomide for Multiple Myeloma
-
Rockefeller’s 2141-V11 Trial Shows Complete Remission in Two Metastatic Cancer Patients
-
Personalized mRNA Cancer Vaccine Succeeds in First Phase 3 Melanoma Trial
-
Dennis Lo Pioneers Liquid Biopsy for Cancer and Prenatal Testing
-
New Research Highlights Rising Internet Addiction Debate
-
Study Suggests Drinking Water With Meals May Lead To Overeating
-
Real-World Oncotype DX Adoption: Rates and Key Challenges
-
Energy Drinks: Youth Marketing, Caffeine Risks Under Scrutiny
-
ADHD Dopamine Dysfunction Disrupts Sleep-Wake Cycles, Study Finds